NON-INSULIN THERAPIES FOR DIABETES MARKET ANALYSIS
However, high cost of newer class of drugs when compared to the conventional drugs are expected to negatively impact the non-insulin therapies for diabetes market growth, especially in regions such as South Asia, where there is large number of patients suffering from type 2 diabetes. For instance, GLP-1 analog costs around US$ 492 for 30 day therapy, whereas Biguanides and sulfonylureas costs around US$ 5-9 for 30 day therapy.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :